Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,3-diphenyl-1H-indole-7-carboxylic acid is a synthetic small molecule belonging to the class of organic compounds known as indoles substituted at the 2 and 3 positions with phenyl groups and at the 7 position with a carboxylic acid group. It has been studied primarily as an experimental compound and is not approved for clinical use. The compound acts as an inhibitor of serine/threonine-protein kinase pim‑1 (PIM1), a proto-oncogene implicated in cell survival and proliferation pathways. Its inhibitory activity against PIM1 kinase suggests potential applications in diseases related to enzymatic dysregulation or cellular dysfunction[1][9][10]. No approved therapeutic indications or marketed products are associated with this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,3-diphenyl-1H-indole-7-carboxylic acid.